Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Rheumatology International|August 8, 2024
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trialsDionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, et al.
Rheumatology (Oxford, England)|May 25, 2023
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumabLeonardo Palazzo, Julius Lindblom, Nursen Cetrez, et al.
Rheumatology (Oxford, England)|April 5, 2024
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activityDionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, et al.
Rheumatology (Oxford, England)|March 14, 2025
Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trialsGiorgia Grosso, Nefeli Giannopoulou, Alexander Tsoi, et al.
Rheumatology Advances in Practice|April 21, 2025
Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithmsJoão Botto, Nursen Cetrez, Dionysis Nikolopoulos, et al.
RMD Open|October 31, 2025
Poor health-related quality of life despite Lupus Low Disease Activity State or Definitions of Remission in systemic lupus erythematosus (SLE) remission in patients with SLE: results from a clinical trial settingIoannis Parodis, Julius Lindblom, Leonardo Palazzo, et al.
Kidney International Reports|September 14, 2023
Effect of Belimumab on Preventing <i>de novo</i> Renal Lupus FlaresIoannis Parodis, Julius Lindblom, Nursen Cetrez, et al.
Rheumatology (Oxford, England)|April 17, 2025
Unsupervised machine learning identifies distinct systemic lupus erythematosus patient endotypes with differential response to belimumabRoberto Depascale, Raffaele Da Mutten, Julius Lindblom, et al.
RMD Open|April 24, 2025
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteriaIoannis Parodis, Julius Lindblom, Leonardo Palazzo, et al.
The Lancet. Rheumatology|August 29, 2024
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trialsIoannis Parodis, Julius Lindblom, Roger A Levy, et al.
Pageof 2